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Summary
PPARg is essential for adipogenesis and metabolic homeostasis. We describe mutations in the DNA and ligand binding
domains of human PPARg in lipodystrophic, severe insulin resistance. These receptor mutants lack DNA binding and tran-
scriptional activity but can translocate to the nucleus, interact with PPARg coactivators and inhibit coexpressed wild-type
receptor. Expression of PPARg target genes ismarkedly attenuated inmutation-containing versus receptor haploinsufficent
primary cells, indicating that such dominant-negative inhibition operates in vivo. Our observations suggest that these
mutants restrict wild-type PPARg action via a non-DNA binding, transcriptional interference mechanism, which may involve
sequestration of functionally limiting coactivators.
Open access under CC BY license.Introduction
The nuclear receptor (NR) peroxisome proliferator-activated re-
ceptor g (PPARg) is a ligand-inducible transcription factor that is
essential for adipocyte differentiation (Tontonoz et al., 1994b;
Barak et al., 1999; Rosen et al., 1999). Alternative splicing and
differential promoter usage generates two protein isoforms:
PPARg2, expressed from a single g2 promoter, contains an ad-
ditional 28 amino-terminal amino acids and is nearly adipose-
specific; PPARg1, whose expression can be regulated by multi-
ple (g1, g3, g4) promoters, is more ubiquitously distributed. In
addition to adipogenesis, PPARg also plays an important role
in adipocyte lipid metabolism, regulating target genes (lipopro-
tein lipase, fatty-acid transport protein, aquaporin) that mediate
triglyceride hydrolysis and fatty acid and glycerol uptake, to-
gether with genes (acylCoA synthetase, PEPCK, glycerol ki-
nase) involved in fatty acid re-esterification and lipid storage
(Lehrke and Lazar, 2005; Savage, 2005). The thiazolidinedione
(TZD) class of antidiabetic agents are synthetic, high-affinity
PPARg ligands (Lehmann et al., 1995) and putative endogenous
activators include fatty acids, eicosanoids, and prostaglandin
derivatives (Desvergne and Wahli, 1999) as well as undefined
ligands produced during adipocyte differentiation (Tzameli
et al., 2004).CELL METABOLISM 4, 303–311, OCTOBER 2006 ª2006 ELSEVIER INCThe most common population genetic variant of PPARg is
a polymorphism replacing alanine for proline at codon 12
(Pro12Ala) in PPARg2, with a meta-analysis of association
studies showing that the Pro allele confers a modest but signif-
icant increase in diabetes risk (Altshuler et al., 2000). The dis-
covery that PPARg is a target for TZDs, which act by enhanc-
ing tissue insulin sensitivity, prompted screening of a cohort of
subjects with severe insulin resistance, with identification of
two missense PPARg mutations (P467L, V290M) in unrelated
cases (Barroso et al., 1999). Functional studies showed that
these mutant receptors retain DNA binding but exhibit signifi-
cant impairment of transcriptional activation and coactivator
recruitment in response to different ligands (Barroso et al.,
1999; Agostini et al., 2004), due to the mutations destabilizing
the carboxyterminal a helix of PPARg (Kallenberger et al.,
2003), which mediates these functions. Consonant with het-
erozygosity in affected subjects and dominant inheritance in
one kindred, the P467L and V290M mutant receptors inhibited
the transcriptional activity of wild-type (WT) PPARg in a domi-
nant-negative manner (Barroso et al., 1999). Subsequently,
two further heterozygous mutations in the ligand binding do-
main (LBD) of PPARg (R425C; F388L) have been described,
with recognition that in addition to insulin resistance the
phenotype also includes a stereotyped pattern of partial. DOI 10.1016/j.cmet.2006.09.003 303
S H O R T A R T I C L Elipodystrophy (PLD) (Hegele et al., 2002; Agarwal and Garg,
2002; Savage et al., 2003).
Following this, we described several individuals who were
heterozygous for a frameshift/premature stop codon mutation,
([A553DAAAiT]fs.185[stop186]-hereafter abbreviated to FSX) in
the DNA binding domain (DBD) of PPARg, with this truncation
mutant lacking DNA binding, transcriptional, and dominant-neg-
ative activity. Significantly, heterozygosity for the FSX mutation
alone was not associated with insulin resistance, but individuals
who were doubly heterozygous, with an additional defect in an
unrelated gene encoding the muscle-specific regulatory subunit
of protein phosphatase 1 (PPP1R3A), exhibited severe insulin
resistance (Savage et al., 2002). Heterozygosity for a single nu-
cleotide substitution in the promoter of human PPARg4 leading
to its altered expression in vitro has been associated with PLD
and insulin resistance in one family, but the authors did not ex-
clude the possibility of interaction with a defect at a second
genetic locus to produce this phenotype (Al-Shali et al., 2004).
Here, we describe the identification of five heterozygous
human PPARg mutations (C114R, C131Y, C162W, R357X,
[A935DC]fs.312[stop315]-hereafter abbreviated to FS315X) not
associated with a PPP1R3A gene defect, in unrelated cases of
lipodystrophic insulin resistance and show that these mutants
inhibit WT receptor action via a non-DNA binding, dominant-
negative mechanism.
Results and Discussion
Heterozygous PPARg mutations are associated
with lipodystrophic insulin resistance
The case histories (see the Supplemental Data available with
this article online) and characterization (Table 1) of index sub-
jects (S1–S5) harboring PPARg mutations indicate many of the
features associated with previously described cases (Barroso
et al., 1999; Hegele et al., 2002; Agarwal and Garg, 2002; Sav-
age et al., 2003). All subjects showed marked fasting hyperinsu-
linaemia (Table 1) with acanthosis nigricans in a subset (S3, S4,
S5), denoting severe insulin resistance; total body fat was re-
duced in all individuals, and imaging indicated a stereotyped
pattern of partial lipodystrophy affecting gluteal (Figure S1)
and peripheral limb depots; hepatic steatosis and marked dys-
lipidaemia (raised triglycerides, low high-density lipoprotein
cholesterol [HDL-C]) with secondary complications (cutaneous
eruptive xanthomata S3, S4; pancreatitis S5) were features of
all cases; several individuals (S2, S3, S5) exhibited early-onset
hypertension.
We sequenced the g4 promoter, coding exons and splice
junctions of PPARG and identified heterozygous, missense mu-
tations in the DBD (S1–S3), or premature stop mutations in the
LBD (S4, S5) of the receptor in index cases. PPARG has also
been sequenced by us in 215 additional subjects, comprising
93 patients from our severe insulin resistance cohort (Barroso
et al., 1999), 48 CEPH individuals of European descent and 27
Europid, hyperinsulinaemic participants in the Ely study (Wil-
liams et al., 1995), and 47 controls from four different ethnic
groups, or sequenced by others in 24 African and 23 CEPH
European individuals (Seattle SNPs project, http://pga.gs.
washington.edu), and other than the Pro12Ala polymorphism
neither these or other mutations have been identified. We also
sequenced PPP1R3A in each proband and identified no muta-304tions or polymorphisms, excluding a second genetic defect at
this locus as described previously (Savage et al., 2002).
Heterozygosity for PPARg mutations in a parent and grand-
parent of S3 and a parent of S5 segregated with phenotype,
constituting a dominant inheritance pattern in two families;
one sibling of S2 with dyslipidaemia and insulin resistance was
heterozygous for the PPARg mutation whereas another geneti-
cally unaffected sibling was biochemically normal; the ascer-
tainable family members of S1 were unaffected and normal
and no relatives of S4 could be contacted (Figure 1B).
PPARg mutants fail to bind DNA and are
transcriptionally inactive
Three missense mutations involve highly conserved cysteine
residues within (C114R, C131Y, C162W) the DBD and two fur-
ther nonsense (R357X) or frameshift/premature stop (FS315X)
mutations truncate the receptor within the central part of its
LBD (Figure 1A), predicting loss-of-function of the mutant pro-
teins. We therefore characterised and compared the properties
of these PPARg mutants with the FSX mutant described previ-
ously (Savage et al., 2002).
The receptor mutants exhibited negligible transcriptional ac-
tivity, lacking constitutive basal activity noted previously with
WT PPARg (Agostini et al., 2004; Zamir et al., 1997) as well as
any response to rosiglitazone, a TZD receptor agonist (Fig-
ure 1C). Such complete loss of function was similar to the FSX
mutant and might be anticipated with analogous truncation
Table 1. Clinical, biochemical, and body composition details
Subject (gender) S1 (F) S2 (F) S3 (F) S4 (F) S5 (F)
Mutation C114R C131Y C162W FS315X R357X
Age (and at
presentation,
year)
41 (34) 42 (35) 31 (19) 13 (8) 35 (26)
BMI (kg/m2)
(nonobese < 30)
30.0 24.2 30.5 25.9 29.3
BP (mmHg)
(< 130/85)
155/95 220/120 150/100* 125/65 125/80*
T2DM/IGT
(age at
diagnosis, yr)
T2DM (41) T2DM (42) IGT (29) T2DM (8) T2DM (26)
PCOS Y Y Y N/A Y
Hepatic steatosis Y Y Y Y Y
TG (mmol/L) (<1.7) 8.9* 4.5 5.0* 8.3* 34.8*
HDL-C (mmol/L)
(>1.29)
0.47* 0.89 0.71* 0.72* 0.56*
FI (pmol/L) (<60) 310 174 220* 475* 170*
Predicted total
body fat (%)
37.4 28.8 38.1 31.3 36.4
Measured total
body fat (%)
26 20.8 23 21.2 nd 26 nd 21 21.1
Measured lower
limb fat (%)
20 17 nd 21 11
Measured truncal
fat (%)
30 27 nd 31 28
BMI, body mass index; BP, blood pressure; T2DM, type 2 diabetes mellitus; IGT,
impaired glucose tolerance; PCOS, polycystic ovarian syndrome; TG, triglycerides;
HDL-C, high-density lipoprotein cholesterol; FI, fasting insulin; Predicted total body
fat was calculated as follows (Black et al., 1983): males % fat = (1.281 3 BMI) 2
10.13: females % fat = (1.48 3 BMI) 2 7.00; measured total and depot-specific
body fat were determined using dual-energy X-ray absorptiometry, with corre-
sponding z scores for total body fat shown as superscript; Hepatic steatosis was
diagnosed according to standard radiological criteria; F, female; healthy adult
values where available are shown in parentheses; asterisk denotes patient studied
on treatment; N/A, not applicable; nd, not determined.CELL METABOLISM : OCTOBER 2006
Non-DNA binding, dominant-negative PPARg mutantsmutants (FS315X, R357X) not possessing the transactivation
(AF2) domain at the receptor carboxyterminus (Figure 1A) (Zamir
et al., 1997; Wu et al., 2003), but the lack of function with DBD
mutants (C114R, C131Y, C162W), prompted further investiga-
tion of their DNA binding properties.
PPARg heterodimerizes with the retinoid X receptor (RXR) and
this complex has been shown to bind a DNA response element
(PPARE), consisting of a direct repeat (DR1) of the consensus
sequence (AGGTCA) separated by a single nucleotide (Ijpen-
berg et al., 1997) and a recent study has suggested that the
stringency of PPARg binding to some response elements is rel-
atively relaxed, not needing complete integrity of its DBD (Tem-
ple et al., 2005). A range of previously documented or predicted
PPAREs from known target genes were therefore tested in elec-
trophoretic mobility shift assays and both DBD and LBD trunca-
tion receptor mutants showed negligible heterodimeric binding
(Figure 1D). To examine interaction of mutant receptors with
RXR, we coexpressed VP16-full length PPARg fusions with
Gal4DBD-RXR in a mammalian two-hybrid assay. In keeping
with preservation of the dimerization interface (Gampe et al.,
2000) within their intact LBD (Figure 1A), the DBD mutants inter-
acted readily whereas the FS315X, R357X, and FSX mutants
lacking this interface failed to be recruited to Gal4-RXR
(Figure S2). It was therefore conceivable that the DBD mutants
could be recruited indirectly to a PPARE by binding RXR
(Gampe et al., 2000), or conversely, that the LBD truncation
mutants might bind a PPARE monomerically as has been docu-
mented with the thyroid hormone receptor (TR) (Lazar et al.,
1991). However, unlike WT receptor, VP16-full length, mutant
PPARg fusions were unable to activate a PPARE-containing re-
porter gene (Figure S3), indicating that like FSX, these PPARg
mutants do not bind DNA directly or indirectly.
PPARg mutants translocate to the nucleus and interact
with cofactors
The intracellular localization of WT PPARg is predominantly nu-
clear (Akiyama et al., 2002) and, analogous to steroid/thyroid
hormone receptors, may be dependent on a putative nuclear
localisation signal (NLS) located between its DBD and LBD
(Figure 1A) (Guiochon-Mantel and Milgrom, 1993; Zhu et al.,
1998). Studies of GFP- PPARg fusions showed that, in keeping
with preservation of the putative NLS, both DBD and LBD trun-
cation mutants localized to the nucleus comparably to WT,
whereas the FSX truncation mutant, which lacks this sequence,
remained cytoplasmic similar to GFP alone (Figure 1E).
We next examined whether the PPARg mutants might also
retain the ability to interact with transcriptional coactivators. Ste-
roid receptor coactivator-1 (SRC1/NCoA1) (Onate et al., 1995)
and PPARg binding protein/thyroid receptor-associated protein
220 (PBP/TRAP220) interact directly with the AF2 domain of
PPARg, with the latter cofactor being required for receptor-
mediated adipogenesis (Zhu et al., 1996, 1997; Ge et al.,
2002). Consistent with preservation of their AF2 domains, pro-
tein-protein interaction assays showed ligand-dependent bind-
ing of SRC1 or TRAP220 to the DBD mutants, but no specific in-
teraction with FSX or LBD truncation mutants, which lack this
region (Figure 1F). Conversely, we hypothesized that the PPARg
LBD truncation mutants would retain the ability to recruit coacti-
vators, which can interact with receptor independently of its AF2
domain. PPARgcoactivator-1 (PGC1), which augments receptor
action in fat cells (Puigserver and Spiegelman, 2003), can bindCELL METABOLISM : OCTOBER 2006PPARg via its DBD and hinge region (aa 128-229) (Puigserver
et al., 1999); PDIP, isolated in a two hybrid assay using the
DBD/hinge region of PPARg (Tomaru et al., 2006), is a coactiva-
tor that also enhances PPARa activity (Surapureddi et al., 2002).
Both PGC1 and PDIP bound WT or FS315X and R357X LBD trun-
cation mutants in protein-protein interaction assays, whereas
the FSX mutant showed negligible interaction (Figure 1G).
PPARg signaling is reduced in mutation-containing
primary cells ex vivo or mutant-expressing cells in vitro
The observation that these PPARg mutants translocate to the
nucleus and interact with coactivators raised the possibility
that they might interfere with WT receptor signaling. The murine
adipocyte P2 (aP2) gene is a classical target of PPARg action
(Tontonoz et al., 1994a; Guan et al., 2005) and the human homo-
log (FABP4) is similarly responsive (Pelton et al., 1999). When
coexpressed with WT PPARg at equivalent levels in 3T3-L1
adipocytes, the DBD and LBD mutants blocked WT receptor
mediated activation of the human aP2/FABP4 gene promoter
comparably to an artificial, dominant-negative PPARg mutant
(AF2) described previously (Gurnell et al., 2000), whereas FSX
lacked dominant-negative inhibitory activity (Figure 2A).
We wished to determine whether such divergent dominant-
negative inhibition by these PPARg mutants versus FSX might
operate in vivo. PPARg is highly expressed in immature dendritic
cells (IDCs) derived from primary human blood monocytes and
mediates marked receptor responsiveness, with strong ligand-
dependent induction of aP2 expression in these cells (Szatmari
et al., 2004). Induction of aP2/FABP4 expression in IDCs con-
taining DBD or LBD PPARg mutations was severely attenuated
compared to responses in control cells from either normal indi-
viduals (WT) or from subjects (IR) with comparable insulin resis-
tance without a PPARg gene defect. Significantly, aP2 induction
in FSX mutation-containing cells was comparable to responses
from control subjects (Figure 2B). We examined other PPARg
target genes, identified from extensive microarray profiling of
normal IDCs (I.S. and L.N., unpublished data) and found that re-
sponses to PPARg agonist in DBD and LBD truncation muta-
tion-containing cells were markedly attenuated whereas FSX
mutation-containing cells exhibited responses that were either
similar or only slightly reduced compared to WT cells (Figure 2C).
PPARgmRNA levels in control and mutation-containing primary
cells were similar (data not shown), suggesting that differential
responsiveness was not due to altered receptor expression.
Furthermore, PPARg mRNA from both WT and R357X alleles
was expressed in mutation-containing IDCs (Figure 2D), indicat-
ing that the R357X transcript is not subject to nonsense-medi-
ated decay (Culbertson, 1999) and both WT and R357X mutant
PPARg proteins were also expressed in these cells (Figure 2E).
Finally, we determined whether dominant-negative inhibition
by a non-DNA binding PPARg mutant could interfere with a re-
ceptor-mediated biological process. Compared to control, WT
PPARg or GFP adenovirus-transduced human preadipocyte
cells, both cellular differentiation (Figure 3A) and aP2 gene ex-
pression (Figure 3B) in cells transduced with C114R mutant
PPARg adenovirus were significantly reduced.
Transcriptional interference via a non-DNA
binding mechanism
We have shown previously that dominant-negative inhibition by
PPARg mutants (P467L, V290M), is mediated by repression of305
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Non-DNA binding, dominant-negative PPARg mutantstarget genes by DNA-bound mutant receptors, analogous to
mechanisms of other mutant nuclear receptors (e.g., the v-erbA
oncogene, TRb mutants in Resistance to Thyroid Hormone,
PZLF-RARa fusion proteins in promyelocytic leukaemia) (Love
et al., 2000). In contrast, the missense DBD and LBD truncation
mutants identified here are unable to bind DNA, yet can inhibit
WT PPARg action, suggesting a different mechanism of tran-
scriptional interference. Competition for shared cofactors by
NRs was postulated to explain mutual antagonism of progester-
one and estrogen receptor signaling (Meyer et al., 1989) and the
subsequent observation that SRC1, a shared coactivator, could
relieve such ‘‘squelching’’, validated this hypothesis (Onate
et al., 1995). Ligand-activated NRs have been shown to inhibit
either their own function (Barettino et al., 1994) or that of heter-
ologous receptors (Zhang et al., 1996) by limiting the availability
of coactivators that are recruited to their transactivation do-
mains. Our observations indicate that non-DNA binding, domi-
nant-negative PPARg mutants can recruit coactivators, sug-
gesting an analogous cofactor sequestration mechanism for
thereby restricting WT receptor function. Evidence suggests
that similar mechanisms operate to inhibit PPAR signaling in
other contexts: analogous to our natural DBD mutants, others
have generated artificial, dominant-negative, PPARg DBD mu-
tants, which block either adipogenesis (Park et al., 2003) or neu-
ral stem cell differentiation (Wada et al., 2006); gORF4 is a newly
identified human PPARg splice variant with a truncated LBD
(aa273), which has dominant-negative activity and is selectively
overexpressed in colorectal neoplasia (Sabatino et al., 2005);
a dominant-negative PPARa splice variant with a truncated
LBD (aa 174), is expressed in human tissues including liver (Ger-
vois et al., 1999). Interestingly, heterozygous, non-DNA binding
mutations in some nuclear receptors do not mediate a pheno-
type: mutations in the DBD of VDR only cause vitamin D resis-
tance in the homozygous state (Malloy et al., 1999); a ‘‘knock-
in’’ mutation in the DBD of murine TRb does not produce thyroid
hormone resistance (Shibusawa et al., 2003). Possibly due to its
pivotal role in regulating transcription of genes mediating both
adipocyte formation and function (Lehrke and Lazar, 2005), we
suggest that PPARg signaling may be particularly sensitive to in-
terference via the postulated ‘‘squelching’’ mechanism, with
deleterious metabolic consequences. A corollary of this may
be that even modest enhancement of normal receptor activity
in key tissues could be beneficial, supporting attempts to de-CELL METABOLISM : OCTOBER 2006velop partial or tissue-specific PPARg agonists (Reginato
et al., 1998; Rocchi et al., 2001; Berger et al., 2003).
Experimental procedures
Sequencing of PPARg and PPP1R3A genes
The PPP1R3A (exons 1-4) and PPARg (exons 1-6, B and promoter region of
PPARg4) genes were amplified using specific primers (available upon re-
quest) and sequenced as decribed previously (Savage et al., 2002).
Construction of PPARg mutants and other vectors
Full lengthWT and mutantPPARg1 cDNAs were cloned inpGEX4T (Amersham
Pharmacia Biotech), pCMX-VP16 (kind gift from R. Evans), pSG424 (Sadowski
and Ptashne, 1989) and pEGFP-C1 (Clontech), to yield GST-PPARg1,
VP16-PPARg1, Gal4DBD-PPARg and GFP-PPARg1 fusions respectively.
Electrophoretic mobility shift assays
Electrophoretic mobility shift assays (EMSA) were performed as described
(Collingwood et al., 1994) with different natural PPAREs: aP2, derived by
alignment of human and murine promoter sequences (Graves et al., 1992);
Adiponectin (Iwaki et al., 2003): ACoABP (Helledie et al., 2002); mCPT1,
(Mascaro et al., 1998); LXRa, (Laffitte et al., 2001); CAP1, (Baumann et al.,
2000); LPL, (Schoonjans et al., 1996); ACoAOx, (Varanasi et al., 1996);
ACoAOx (Zamir et al., 1997).
Transfection assays
293EBNA cells, cultured in DMEM/10%FCS were transfected with Lipofect-
amine2000- or calcium phosphate-mediated in 96- or 24-well plates respec-
tively and assayed for luciferase and b-galactosidase activity as described
(Collingwood et al., 1994) following 36 hr with or without ligand. 3T3-L1
adipocyte cells were cultured and transfected with Lipofectamine2000 in
24-well plates as described above.
Cellular localisation of EGFP-tagged mutants
293EBNA cells, grown on glass well slides were transfected using Lipofect-
amine 2000 with 1mg of EGFP-PPARg1 fusions, fixed with 4% paraformalde-
hyde, mounted using vectashield and fluorescence was visualized by digital
microscopy.
Peripheral blood monocyte purification and IDC culture
With ethical approval, monocytes were harvested from peripheral blood by Fi-
coll gradient centrifugation and immunomagnetic cell separation using anti-
CD14-conjugated microbeads (VarioMACS; Miltenyi Biotec), resuspended
in 6-well plates at a density of 1.5 3 106 cells/ml and cultured in RPMI 1640
plus 10% FBS containing 800U/ml GM-CSF (Leucomax) and 500U/ml IL-4
(Peprotech) to generate IDCs as described (Sallusto and Lanzavecchia,
1994) with or without exposure to ligand for 24 hr.Figure 1. Identification and characterization of loss-of-function mutations in human PPARg
A) Schematic representation of the three major domains of PPARg, showing the locations of the five mutations (C114R, C131Y, C162W, FS315X, and R357X – PPARg1
nomenclature) and the previously reported FSX mutation. NLS, nuclear localisation signal; RXR ID, retinoid X receptor interaction domain; AF2, activation function 2 domain.
B) Family pedigrees showing genotypes (N, wild-type allele; M, mutant allele; NA, not available) and phenotypes (colored segments denote the presence of specific traits:
green, type 2 diabetes mellitus/impaired glucose tolerance/hyperinsulinaemia; yellow, hypertriglyceridaemia; blue, hypertension; red, ischemic heart disease). Squares and
circles represent male and female family members; slashed symbols denote deceased family members and arrows denote probands.
C) PPARg mutants are unable to mediate ligand-dependent transactivation. 293EBNA cells were transfected with 100 ng of wild-type (WT), mutant, or empty (pcDNA3) ex-
pression vectors, together with 500 ng of (PPARE)3TKLUC reporter construct and 100 ng of Bos-b-gal internal control plasmid, and increasing concentrations of rosiglitazone.
Results are expressed as a percentage of the maximum activation with WT PPARg1 and represent the mean6 SEM of at least three independent experiments in triplicate.
D) PPARg mutants are unable to bind to DNA. EMSA with in vitro translated wild-type (WT) or mutant PPARg1 (C114R, C131Y, C162W, FS315X, R357X, or FSX) and RXR
proteins coincubated with oligonucleotide duplexes corresponding to various natural PPAREs. aP2, adipocyte protein 2; ACoABP, acyl coenzyme A binding protein;
mCPT1, muscle carnitine palmitoyl transferase 1; LXRa, liver X receptor a; CAP, cbl-associated protein; LPL, lipoprotein lipase, ACoAOx, acyl coenzyme A oxidase;
h, human; m, mouse; r, rat; RL, reticulocyte lysate.
E) The C114R, C131Y, C162W, FS315X, and R357X mutants translocate to the nucleus whereas the FSX mutant remains cytoplasmic. 293EBNA cells were transfected as
described. Top panels show DAPI-staining (blue) of nuclei, middle panels the cellular localisation of GFP-tagged receptors, and lower panels merged images.
F)The DBD PPARgmutants recruit SRC1 and TRAP220 coactivators, whereas the FS315X, R357X, and FSX truncation mutants do not interact. GST alone or WT and mutant
GST-PPARg fusion proteins were tested with 35S-labeled in vitro translated SRC1 (upper panel) or TRAP220 (lower panel) in the absence or presence of rosiglitazone. Coo-
massie-stained gels confirmed comparable protein loading (data not shown). G) The LBD truncation mutants (FS315X, R357X) recruit PGC1a and PDIP1a coactivators,
whereas the FSX mutant fails to interact. GST alone or WT and mutant GST-PPARg fusion proteins were tested with 35S-labeled in vitro translated human PGC1a and human
PDIP1a in the absence of ligand. Coomassie-stained gels confirmed comparable protein loading (data not shown).307
S H O R T A R T I C L EFigure 2. PPARg mutants exhibit dominant-negative activity
A) The C114R, C131Y, C162W, FS315X, and R357X PPARg mutants inhibit transactivation by wild-type (WT) receptor, comparably to AF2, an artificial PPARg mutant
described previously, whereas the FSX mutant lacks dominant-negative activity (upper panel). 3T3-L1 cells were cotransfected with 33 ng of WT receptor plus an equal
amount of either empty (pcDNA3) or WT or mutant expression vector, together with 265 ng of human aP2LUC reporter plasmid and 65 ng of the internal control plasmid
Bos-b-gal. The dotted and dashed lines denote transcriptional activity of WT receptor in the absence and presence of ligand respectively. Results are expessed as fold
induction relative to empty vector (pcDNA3 + pcDNA3) and represent the mean6 SEM of at least three independent experiments in triplicate. Expression of wild-type and
mutant receptor proteins was confirmed by Western blotting (lower panel) and the positions of WT, C114R, C131Y, C162W, and AF2 PPARg (open arrow) and FSX, FS315X
and R357X truncation mutants (solid arrows) are indicated.
B and C) Ligand-dependent regulation of PPARg target genes in IDCs from subjects with PPARg mutations. (B) Induction of the aP2 gene by rosiglitazone, measured by
qPCR, is markedly impaired in IDCs derived from subjects with the C114R, C131Y, FS315X, and R357X mutations, compared to responses in cells from normal (WT), se-
verely insulin resistant (IR) subjects without mutations in PPARg and cells with the FSX, haploinsufficient, mutation. Results represent the mean6 SEM of more than three
independent experiments in triplicate, except for cells with the FS315X mutation where a single representative experiment is shown. (C) Relative expression of several
PPARg target genes (5 downregulated and 5 upregulated) in WT and mutation-containing (FSX, C114R, R357X) IDCs, measured by qPCR using TLDA. Red indicates
higher, and blue lower, levels of gene expression relative to rosiglitazone-treated (1000 nM) WT cells, whose responses are uniformly designated yellow. Fold changes
in expression of each gene in rosiglitazone (RSG) versus vehicle (DMSO) treated WT cells are also listed.
DandE) The R357X PPARgmutant is expressed in IDCs. (D) PPARg cDNA flanking the R357 codon was amplified by RT-PCR in IDCs from patient S5 and a control subject.
Cac81 enzyme digestion of PCR products derived from the WT allele yields two fragments (161 and 74 bp), whereas abolition of this restriction site in the R357X mutant
allele yields a larger 235 bp product. (E) Whole-cell lysates of WT and R357X mutant IDCs and 293EBNA cells transfected with R357X mutant were immunoprecipitated and
Western blotted. The positions of WT PPARg (open arrow), R357X (solid arrow), and nonspecific bands (solid arrowheads) are indicated.Quantitative real-time PCR analysis of gene expression
100ng of total RNA from IDCs, isolated using TRIZOL (Invitrogen), was re-
verse transcribed and analyzed by Taqman quantitative real-time PCR
(qPCR) as described (Szatmari et al., 2004). The sequences of primers and
probes are available upon request.
Taqman qPCR low density arrays (TLDA) were used to quantify the ex-
pression of multiple target genes in IDCs, according to the manufacturer’s
instructions.308To obtain cDNA, RNA was reverse transcribed using a High Capacity
cDNA Archive kit (Applied Biosystems). The following commercially available
Taqman assays (Applied Biosystems) were used: ADRP/ADFP
(Hs00605340_m1), APOC1 (Hs00155790_m1), CLDN1 (Hs00221623_m1),
aP2/FABP4 (Hs00609791_m1), CLECSF5 (Hs00183780_m1), CD1E
(Hs00229421_m1), MYO1B (Hs00362654_m1), IL1R2 (Hs00174759_m1),
OAS1 (Hs00242943_m1), p30 (Hs00396457_m1), cyclophilinA/PPIA
(Hs99999904_m1). The comparative Ct method was used to quantifyCELL METABOLISM : OCTOBER 2006
Non-DNA binding, dominant-negative PPARg mutantstranscripts and normalize to cyclophilinA expression levels, which did not
vary with ligand treatment. Thereafter, data were further normalized to ex-
pression levels in ligand-treated WT IDC samples using GeneSpring 7.2 soft-
ware (Agilent).
RFLP analysis of PPARg transcripts
PPARg cDNAs were amplified from WT or R357X mutation-containing IDCs
by RT-PCR using forward (CTCCTTGATGAATAAAGATGGGG) and reverse
(ATGTCTTCAATGGGCTTCACAT) primers, the PCR products were digested
Figure 3. Adenoviral-mediated expression of the C114R PPARg mutant inhibits
human preadipocyte differentiation
Chub-S7 human preadipocyte cells were infected with comparable efficiency us-
ing recombinant adenoviruses expressing GFP, GFP-WT, or GFP-C114R mutant
PPARg and differentiated in the presence of rosiglitazone (100nM).
A) Fully differentiated Chub-S7 cells fixed and stained with oil red O.
B) aP2 expression quantitated by real-time qPCR at days 0, 3, 5, and 7 postdiffer-
entiation with results representing the mean 6 SEM of at least three independent
experiments in triplicate.
C) Western blotting of Chub-S7 cells at day 4 posttransduction with recombinant
adenoviruses confirming comparable levels of total receptor expression. Nondif-
ferentiated, (day 0) nontransduced, cell extracts (ND) are shown for comparison.
The positions of PPARg (open arrow) and nonspecific band (solid arrowhead)
are indicated.CELL METABOLISM : OCTOBER 2006with Cac8I enzyme (New England Biolabs) and analyzed by agarose gel
electrophoresis.
Immunoprecipitation and Western blot analysis
IDCs, harvested from 200ml of peripheral blood, were lysed in RIPA buffer
containing a protease inhibitor cocktail (Roche) and cell supernatants immu-
noprecipitated using a mouse monoclonal anti-PPARg antibody (K8713, Per-
seus Proteomics) and analyzed by SDS-PAGE. Western blotting was carried
out using a rabbit polyclonal anti-PPARg antibody (H-100, Santa Cruz
Biotechnology).
Adenovirus construction and expression
Recombinant type 5 adenoviruses (Ad5) expressing GFP alone or with either
WT or C114R mutant PPARg1 were generated using the AdEasy Vector Sys-
tem (Quantum Biotechnologies, Montreal), amplified and purified as de-
scribed (Gurnell et al., 2000). 6-well plates of Chub-S7 human preadipocyte
cells were cultured and infected with 2x107 pfu/well of recombinant virus 24
hr prior to differentiation in the presence of 100nM rosiglitazone as described
(Darimont et al., 2003). Comparable infection efficiency was verified by fluo-
rescence microscopy with subsequent qPCR analysis on days 0, 3, 5 and 7.
Fully differentiated cells were fixed and stained with Oil Red-O as described
(Adams et al., 1997).
Supplemental data
Supplemental Data include Supplemental Experimental Procedures and
three figures and can be found with this article online at http://www.
cellmetabolism.org/cgi/content/full/4/4/303/DC1/.
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